You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Funded Evidence-Informed Regimens

Drug and regimen monographs and information sheets for patients provide information on dosing and administering cancer treatment protocols. They are for general reference and are not meant to replace prescribing information or physician recommendations.

If you have questions about ST-QBP funding on our website, please visit our Frequently Asked Questions page.

Find enhanced Regimen Patient Information Sheets, created in collaboration with patient and family advisors.

Regimens

17 Items
Cancer Type: Gastrointestinal, Neuroendocrine (GI)     
Intent: Palliative
Funding:
ODB - General Benefit
    lanreotide
May 2018
Cancer Type: Hematologic, Myelodysplastic Syndrome (MDS)     
Intent: Palliative
Funding:
Exceptional Access Program
    lenalidomide - Anemia due to MDS, with specific criteria
Sep 2018
Cancer Type: Hematologic, Multiple Myeloma     
Intent: Palliative
Funding:
Exceptional Access Program
    lenalidomide - For the maintenance treatment of patients with newly diagnosed multiple myeloma, following autologous stem-cell transplantation, according to specific criteria.
Sep 2018
Cancer Type: Hematologic, Lymphoma - Non-Hodgkin's High Grade     
Intent: Palliative
Drugs Used:
lenalidomide (Unfunded)
Dec 2017
Cancer Type: Hematologic, Lymphoma - Non-Hodgkin's High Grade     
Intent: Curative
Drugs Used:
lenalidomide (Unfunded)
Feb 2018
Cancer Type: Endocrine, Thyroid     
Intent: Palliative
Funding:
Exceptional Access Program
    For the treatment of patients with locally recurrent or metastatic, progressive, radioactive-iodine-refractory differentiated thyroid cancer (DTC) according to criteria
Oct 2017
Cancer Type: Breast     
Intent: Adjuvant
Funding:
ODB Limited Use
  • letrozole - As an alternative to tamoxifen for the adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer for a maximum of five years
ODB Limited Use
  • letrozole - Treatment of hormone receptor positive early breast cancer in postmenopausal women who have received 5 years of adjuvant tamoxifen therapy
May 2016
Cancer Type: Breast     
Intent: Palliative
Funding:
ODB Limited Use
  • letrozole - Treatment of metastatic breast cancer in hormone receptor positive postmenopausal women
May 2016
Cancer Type: Gynecologic, Ovary     
Intent: Palliative
Drugs Used:
letrozole (Unfunded)
Oct 2017
Cancer Type: Breast     
Intent: Palliative
Funding:
Exceptional Access Program
    For the treatment of post-menopausal women with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer according to clinical criteria
ODB Limited Use
    letrozole - Treatment of metastatic breast cancer in hormone receptor positive postmenopausal women
Aug 2018
Cancer Type: Breast     
Intent: Palliative
Funding:
ODB Limited Use
    letrozole - Treatment of metastatic breast cancer in hormone receptor positive postmenopausal women
Drugs Used:
ribociclib (Unfunded)
Oct 2018
Cancer Type: Hematologic, Leukemia - Acute Lymphoblastic (ALL)     
Intent: Curative
Jan 2018